Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign

Joint Bone Spine

Volumn 80, Issue 3, 2013, Pages 280-286

  Bisson Vaivre, Aurélia ^a   Alcaix, Didier ^b   Zarnitsky, Charles ^b   Pueyo, Laurent ^c   Daragon, Alain ^a   Lanfant Weybel, Karine ^a   Dacher, Jean Nicolas ^d   Vittecoq, Olivier ^a   Le Loët, Xavier ^a   Goëb, Vincent ^a,c  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^b Jacques Monod Hospital   (France)

^c Centre Médical des Armées d'Evreux   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Anti TNF; ASAS; Imaging; Spondyloarthritis

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA B27 ANTIGEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL EVALUATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SCREENING; DRUG TREATMENT FAILURE; EUROPE; FEMALE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROPENSITY SCORE; RADIODIAGNOSIS; RETROSPECTIVE STUDY; SPONDYLARTHRITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MULTICENTER STUDY; PREDICTIVE VALUE; RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SPONDYLARTHRITIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878373347     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.08.003     Document Type: Article

References (27)

1. Mau W., Zeidler H., Mau R., et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year follow-up. J Rheumatol 1988, 1:1109-1114.
2. Rudwaleit M., van der Heijde D., Landewé R., et al. The development of assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
3. Dougados M., van der Linden S., Juhlin R., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34:1218-1227.
4. Rudwaleit M., Jurik A., Hermann K., et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009, 68:1520-1527.
5. Anderson J., Baron G., van der Heijde D., et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886.
6. Brandt J., Listing J., Sieper J., et al. Development and preselection of criteria for short-term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004, 63:1438-1444.
7. Haibel H., Rudwaleit M., Listing J., et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008, 58:1981-1991.
8. Rudwaleit M., Haibel H., Baraliakos X., et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009, 60:717-727.
9. Feldtkeller E., Bruckel J., Khan M. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol 2000, 12:239-247.
10. Rojas-Vargas M., Muñoz-Gomariz E., Escudero A., et al. First signs and symptoms of spondyloarthritis - data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). Rheumatology (Oxford) 2009, 48:404-409.
11. Van der Heijde D., Dijkmans B., Geusens P., et al. Ankylosing spondylitis study for the evaluation of recombinant infliximab therapy study group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591.
12. Braun J., Baraliakos X., Listing J., et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008, 67:340-345.
13. Van der Heijde D., Da Silva J., Dougados M., et al. Etanercept Study 314 Investigators. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:1572-1577.
14. Davis J., van der Heijde D., Braun J., et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005, 64:1557-1562.
15. Van der Heijde D., Kivitz A., Schiff M., et al. ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146.
16. Rudwaleit M., Claudepierre P., Wordsworth P., et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36:801-808.
17. Almodóvar R., Carmona L., Zarco P., et al. Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of the measures of activity, function and radiological damage. Clin Exp Rheumatol 2010, 28:S33-S39.
18. Lee W., Reveille J., Davis J., et al. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis 2007, 66:633-638.
19. Feldtkeller E., Khan M., van der Heijde D., et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003, 23:61-66.
20. Rudwaleit M., Metter A., Listing J., et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006, 54:569-578.
21. Vander Cruyssen B., Ribbens C., Boonen A., et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007, 66:1072-1077.
22. Sampaio-Barros P., Bortoluzzo A., Conde R., et al. Undifferentiated spondyloarthritis: a long-term follow-up. J Rheumatol 2010, 37:1195-1199.
23. Brandt J., Bollow M., Häberle J., et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 1999, 38:831-836.
24. Bennett A., McGonagle D., O'Connor P., et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008, 58:3413-3418.
25. Glintborg B., Ostergaard M., Krogh N., et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010, 69:2002-2008.
26. Braun J., Brandt J., Listing J., et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003, 48:2224-2233.
27. Barkham N., Keen H., Coates L., et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009, 60:946-954.